In the summer of 2011, Jim Frates, CFO of Alkermes faced choices about the best way to invest the assets of Dublin, Ireland-based Elan Drug Technologies (EDT) - a deal which was anticipated to narrow the fall.
The case describes the history of Alkermes, provides information about the planned combiner, and explains the financing options. The case gives pupils the chance to assess the attractiveness of the merger to assess the function CFOs play in biopharmaceutical businesses, and to choose a funding option.
Transforming Alkermes into a Global Biopharmaceutical Company Case Study Solution
This is just an excerpt. This case is about FINANCE & ACCOUNTING
PUBLICATION DATE: May 28, 2015 PRODUCT 2015 PRODUCT #: 215079-PDF-ENG
Related Case Solutions & Analyses:
Thunderball (C)
Diageo and East African Breweries Ltd.: Tapping New Markets for Social Good
Lockheed Martin’s Acquisition of NationScape Inc.
Kalamazoo Zoo
Temasek’s Offer to Buy Olam International
Sino-Forest (A)
KKR: Leveraging Sustainability
Enman Oil, Inc. (D)
Fundamental Enterprise Valuation: Invested Capital
Rockboro Machine Tools Corporation
